Drug Trial Radar · NCT07154069
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
802
Planned (sponsor's estimate)
Start
Nov 13, 2025
Primary completion
Sep 2031
Study completion Sep 2033
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To assess whether radiotherapy alone is non-inferior to concurrent chemoradiotherapy with respect to event-free survival and superior in reducing treatment-related nausea in low-risk locoregionally advanced nasopharyngeal carcinoma patients who achieve complete or partial response and undetectable serum EBV-DNA following induction chemoimmunotherapy. 2. To evaluate whether adjuvant capecitabine and immunotherapy after concurrent chemoradiotherapy improves event-free survival compared to adjuvant immunotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma patients with stable disease or detectable serum EBV-DNA after induction chemoimmunotherapy.
Conditions
- Nasopharyngeal Cancinoma (NPC)
Interventions
Radical radiotherapy of nasopharynx and neckRadiation
Radical radiotherapy of nasopharynx and neck
CapecitabineDrug
Adjuvant metronomic capecitabine (650 mg/m² twice daily) for one year
Concurrent chemoradiotherapy (cCRT)Drug
Concurrent chemoradiotherapy
ToripalimabDrug
Adjuvant Toripalimab (240mg day1, Q3W )
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: 3 year
- Incidence rates of vomiting as assessed by CTCAE v5.0Time frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.